{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:49:41Z","timestamp":1790887781866,"version":"4.1.0"},"reference-count":31,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2019,7,24]]},"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Few studies have investigated the prevalence of adverse drug reactions (ADRs) leading to hospitalisation in Japan. The aim of this study was to determine the prevalence of ADRs leading to hospitalisation and to evaluate the preventability of these ADRs in Japan.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>A single-centre cross-sectional study using electronic medical records.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>Acute care hospital.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>All 1545 consecutive hospital admissions to an internal medicine ward due to acute medical illnesses from April 2017 to May 2018. The median patient age was 79 years (IQR 66\u201387), and the proportion of women was 47.9%.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Outcome measures<\/jats:title>\n                  <jats:p>The primary outcome was the proportion of hospitalisations caused by ADRs among all hospitalisations. All suspected cases of ADRs were independently evaluated by two reviewers, and disagreements were resolved by discussion. The causality assessment for ADRs was performed by using the WHO-Uppsala Monitoring Committee criteria. The contribution of ADRs to hospitalisation and their preventability were evaluated based on the Hallas criteria.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 1545 hospitalisations, 153 hospitalisations (9.9%, 95% CI 8.4% to 11.4%) were caused by 200 ADRs. Cardiovascular agents (n=46, 23.0%), antithrombic agents (n=33, 16.5%), psychotropic agents (n=29, 14.5%) and non-steroidal anti-inflammatory drugs (n=24, 12.0%) accounted for approximately two-thirds of all ADRs leading to hospitalisation. Of 153 hospitalisations caused by ADRs, 102 (66.7%) were judged to be preventable.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Similar to other countries, one in every ten hospitalisations is caused by ADRs according to data from an internal medicine ward of a Japanese hospital. Most of these hospitalisations are preventable. Some efforts to minimise hospitalisations caused by ADRs are needed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2019-030515","type":"journal-article","created":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T12:39:27Z","timestamp":1565008767000},"page":"e030515","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":16,"title":["Prevalence of hospitalisation caused by adverse drug reactions at an internal medicine ward of a single centre in Japan: a cross-sectional study"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5899-4760","authenticated-orcid":false,"given":"Junpei","family":"Komagamine","sequence":"first","affiliation":[{"name":"Internal Medicine, National Hospital Organization Tochigi Medical Center, Utsunomiya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Internal Medicine, National Hospital Organization Tochigi Medical Center, Utsunomiya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,8,5]]},"reference":[{"key":"2025101814261532000_9.8.e030515.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02799-9"},{"key":"2025101814261532000_9.8.e030515.2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1L037"},{"key":"2025101814261532000_9.8.e030515.3","first-page":"2079","article-title":"A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting","volume":"9","author":"Alhawassi","year":"2014","journal-title":"Clin Interv Aging"},{"key":"2025101814261532000_9.8.e030515.4","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00228-017-2225-3","article-title":"Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis","volume":"73","author":"Oscanoa","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"2025101814261532000_9.8.e030515.5","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A225"},{"key":"2025101814261532000_9.8.e030515.6","doi-asserted-by":"crossref","first-page":"110","DOI":"10.14442\/general.15.110","article-title":"Polypharmacy and adverse drug events leading to acute care hospitalization in Japanese elderly","volume":"15","author":"Fushiki","year":"2014","journal-title":"General Medicine"},{"key":"2025101814261532000_9.8.e030515.7","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-002-0467-0"},{"key":"2025101814261532000_9.8.e030515.8","unstructured":"Uppsala Monitoring Centre . The use of the WHO-UMC system for standardised case causality assessment. Available: https:\/\/www.who-umc.org\/media\/164200\/who-umc-causality-assessment_new-logo.pdf [Accessed 21 Feb 2019]."},{"key":"2025101814261532000_9.8.e030515.9","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"2025101814261532000_9.8.e030515.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1990.tb00199.x"},{"key":"2025101814261532000_9.8.e030515.11","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015570104121"},{"key":"2025101814261532000_9.8.e030515.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02698.x"},{"key":"2025101814261532000_9.8.e030515.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1103053"},{"key":"2025101814261532000_9.8.e030515.14","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.45.1758"},{"key":"2025101814261532000_9.8.e030515.15","unstructured":"International Narcotics Control Board . Availability of internationally controlled drugs: ensuring adequate access for medical and scientific purposes. Chapter III. Psychotropic substances. Available: https:\/\/www.incb.org\/documents\/Publications\/AnnualReports\/AR2015\/English\/Supp\/AR15_Availability_E_Chapter_III.pdf [Accessed 3 Mar 2019]."},{"key":"2025101814261532000_9.8.e030515.16","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/S0140-6736(05)76729-5","article-title":"Japanese doctors\u2019 attitudes to complementary medicine","volume":"354","author":"Imanishi","year":"1999","journal-title":"Lancet"},{"key":"2025101814261532000_9.8.e030515.17","doi-asserted-by":"crossref","DOI":"10.1186\/s12906-018-2228-3","article-title":"Prevalence of the potentially inappropriate Kampo medications to be used with caution among elderly patients taking any prescribed Kampo medications at a single centre in Japan: a retrospective cross-sectional study","volume":"18","author":"Komagamine","year":"2018","journal-title":"BMC Complement Altern Med"},{"key":"2025101814261532000_9.8.e030515.18","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2013.00177","article-title":"The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety","volume":"4","author":"Ekor","year":"2014","journal-title":"Front Pharmacol"},{"key":"2025101814261532000_9.8.e030515.19","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0250-z"},{"key":"2025101814261532000_9.8.e030515.20","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00228-016-2170-6","article-title":"Hospitalizations due to preventable adverse reactions-a systematic review","volume":"73","author":"Patel","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"2025101814261532000_9.8.e030515.21","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.13702."},{"key":"2025101814261532000_9.8.e030515.22","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afu145"},{"key":"2025101814261532000_9.8.e030515.23","doi-asserted-by":"publisher","DOI":"10.1197\/j.aem.2004.08.056"},{"key":"2025101814261532000_9.8.e030515.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2009.10.008"},{"key":"2025101814261532000_9.8.e030515.25","doi-asserted-by":"publisher","DOI":"10.1136\/emermed-2011-200482"},{"key":"2025101814261532000_9.8.e030515.26","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jemermed.2013.11.124","article-title":"Adverse drug event nonrecognition in emergency departments: an exploratory study on factors related to patients and drugs","volume":"46","author":"Roulet","year":"2014","journal-title":"J Emerg Med"},{"key":"2025101814261532000_9.8.e030515.27","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.320.7241.1036","article-title":"Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. French pharmacovigilance centres","volume":"320","author":"Pouyanne","year":"2000","journal-title":"BMJ"},{"key":"2025101814261532000_9.8.e030515.28","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629020-00006"},{"key":"2025101814261532000_9.8.e030515.29","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2008.3"},{"key":"2025101814261532000_9.8.e030515.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa020703"},{"key":"2025101814261532000_9.8.e030515.31","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200831010-00003"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-030515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:26:24Z","timestamp":1760822784000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-030515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":31,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8,5]]},"published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1136\/bmjopen-2019-030515"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-030515","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}